Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04851119 · ClinicalTrials.gov registry record · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
A Phase 1 study of Melanoma and Neuroblastoma, sponsored by Children's Oncology Group.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 147
- Enrollment target
- 20
- Study locations
NCT04851119 is a Phase 1 study of Melanoma and Neuroblastoma that is actively recruiting participants, run by Children's Oncology Group. The registered enrollment target is 147 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT04851119, a Phase 1 study of Melanoma and Neuroblastoma, is actively recruiting participants, sponsored by Children's Oncology Group.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 147 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE X-Ray Imaging
- DRUG Tegavivint
- PROCEDURE Dual X-ray Absorptiometry
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital of Orange County - Orange
- Lucile Packard Children's Hospital Stanford University - Palo Alto
- UCSF Medical Center-Mission Bay - San Francisco
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Alabama
- Children's Hospital of Alabama - Birmingham
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital - Atlanta
Illinois
- Lurie Children's Hospital-Chicago - Chicago
Indiana
- Riley Hospital for Children - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2021-11-08 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04851119
The ClinicalTrials.gov registry entry for NCT04851119 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (79% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT04851119 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Pennsylvania, Alabama.
Frequently Asked Questions
What is clinical trial NCT04851119 about?
NCT04851119 is a clinical study titled "Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors". This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help...
What is the current status of trial NCT04851119?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2021-11-08. Estimated completion is 2028-06-30.
What conditions does trial NCT04851119 study?
This clinical trial studies the following conditions: Melanoma, Neuroblastoma, Pancreatic Ductal Adenocarcinoma, Colorectal Carcinoma, Ovarian Carcinoma.
What interventions are being tested in trial NCT04851119?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), X-Ray Imaging (PROCEDURE), Tegavivint (DRUG), Dual X-ray Absorptiometry (PROCEDURE).
Who is sponsoring clinical trial NCT04851119?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04851119 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.